CIAS
EIGR

Capital Investment Advisory Services’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Capital Investment Advisory Services’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-17
Closed -$5K – 1486
2019
Q2 		$5K Buy
+17
New +$5.89K ﹤0.01% 1154

Other funds holding EIGR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Capital Investment Advisory Services's EIGR Position: Q3 2019 in Review

Capital Investment Advisory Services sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2019, closing a stake of 17 shares — an estimated $5K sold.

Capital Investment Advisory Services first reported a position in EIGR in Q2 2019 and held it in 1 quarter. The position peaked at $5K in Q2 2019. 84 funds tracked by Wall St. Rank hold EIGR as of Q3 2019.

  • Capital Investment Advisory Services reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 17 Eiger BioPharmaceuticals, Inc. shares in Q3 2019, an estimated $5K.
  • Capital Investment Advisory Services first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Capital Investment Advisory Services's Eiger BioPharmaceuticals, Inc. position peaked at $5K in Q2 2019.
  • 84 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2019.

Based on Capital Investment Advisory Services's 13F filing for Q3 2019, filed 17 Oct 2019.